Kim L. Isaacs MD PhDProfessor of Medicine, UNC Inflammatory Bowel Disease Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina
Kim L. Isaacs is Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, at the University of North Carolina, Chapel Hill.
Dr Isaacs received her Doctor of Philosphy degree in Basic Health Sciences/Pathology from the State University of New York at Stony Brook in 1981 followed by her Doctor of Medicine Degree in 1984. Her postgraduate training included residency and chief residency in Internal Medicine from 1984-1988 and Fellow, Division of Digestive Diseases and Nutrition at the University of North Carolina, North Carolina Memorial Hospital from 1988-1991. She joined the faculty of the division of Gastroenterology and Hepatology at the University of North Carolina in 1991. She is the associate director of the Multi-disciplinary Inflammatory Bowel Disease clinic at the University of North Carolina. She is active in the clinical care of patients in inflammatory bowel disease with special interests in pouchitis, the role of capsule endoscopy in the management of inflammatory bowel disease and in women’s issues in inflammatory bowel disease. In addition clinical activities include an active endoscopic practice. She continues to be very active in the fellowship program after completing a 10 year term as gastroenterology fellowship director at the University of North Carolina and currently serving as the assistant program director.
In addition to extensive publications and invited talks, Dr Isaacs has served as principal and investigator of numerous clinical trial studies in the management and treatment of gastrointestinal disorders, including ulcerative colitis, pouchitis, and Crohn's disease.
DisclosuresDr. Isaacs is on a Data Safety Monitoring Committee for a Janssen product, and her institution receives clinical trial support for multicenter clinical trials from Abbvie, Janssen, UCB, Roche, Lily, and Genentech.
Recent Contributions to PracticeUpdate:
- Fecal Calprotectin Level Predicts the Need for Rescue Therapy in Patients Hospitalized With Severe Colitis
- IBD Is Associated With Age-Attenuated Risk for Chronic Kidney Disease
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- Methotrexate Is Not Superior to Placebo in Inducing Steroid-Free Remission in Ulcerative Colitis